top talk (ep 4) - checkmate 743: dual immunotherapy has significant survival benefit in mpm
Published 3 years ago • 88 plays • Length 26:27Download video MP4
Download video MP3
Similar videos
-
5:22
checkmate 743: first-line nivolumab plus ipilimumab vs chemotherapy in patients with unresectabl...
-
2:06
checkmate-743 study in mesothelioma
-
5:18
checkmate577: nivolumab in ec/gejc
-
1:01
dr. heymach on nivolumab for lung cancer
-
55:59
ed forum chat series: understanding immunotherapy
-
0:56
targeting the tumor vasculature in mesothelioma
-
6:51
success for ipilimumab and nivolumab combo in advanced melanoma
-
1:13
checkmate 067: nivolumab plus ipilimumab combination therapy in advanced melanoma
-
1:25
breast cancer molecular testing – more tools in the toolbox: 2023 ku breast cancer year in review
-
1:33
dr. wolchok on the safety profile in checkmate-067 in melanoma
-
1:25
results of checkmate 039 trial of nivolumab in combination with ipilimumab for hodgkin lymphoma
-
2:18
dr. jeffrey weber on checkmate-064 trial for advanced melanoma
-
1:38
patients in checkmate 067 demonstrate durable complete responses
-
5:06
phase 3 checkmate - 214
-
6:13
checkmate-227: testing ipilimumab/nivolumab in nsclc
-
27:18
adjuvant and neoadjuvant dilemmas
-
2:44
cancer immunotherapy with nivolumab plus ipilimumab vs. chemotherapy: insights from checkmate 227